Real-Life Anti-Tumour Necrosis Factor Experience in > 500 Paediatric United Kingdom Inflammatory Bowel Disease Patients.
暂无分享,去创建一个
A. Akobeng | R. Russell | R. Muhammed | L. Williams | J. Fell | F. Torrente | H. Jenkins | M. Elawad | R. M. Beattie | N. Croft | M. Cosgrove | V. Merrick | B. Vadamalayan | S. Loganathan | M. Auth | A. Rodrigues | C. Charlton | V. Zamvar | S. Mitton | M. Furman | S. Chong | D. Wilson | M. Morris | K. Mortier | R. Beattie
[1] A. Griffiths,et al. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.
[2] Frederic D Bushman,et al. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease , 2015, Inflammatory bowel diseases.
[3] R. Russell,et al. Anti-TNF therapy for paediatric IBD: the Scottish national experience , 2015, Archives of Disease in Childhood.
[4] A. Griffiths,et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. , 2014, Journal of Crohn's & colitis.
[5] Heather B. Blunt,et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[6] A. Griffiths,et al. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee , 2014, Gut.
[7] M. Milošević,et al. The IMPACT-III (HR) questionnaire: a valid measure of health-related quality of life in Croatian children with inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.
[8] J. Rhodes,et al. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit , 2013, Alimentary pharmacology & therapeutics.
[9] R. Russell,et al. Contemporary Outcomes for Ulcerative Colitis Inpatients Admitted to Pediatric Hospitals in the United Kingdom , 2013, Inflammatory bowel diseases.
[10] A. Griffiths,et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] A. Griffiths,et al. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions , 2012, Inflammatory bowel diseases.
[12] A. Akobeng,et al. Validation of an Instrument to Measure Quality of Life in British Children With Inflammatory Bowel Disease , 2011, Journal of pediatric gastroenterology and nutrition.
[13] C. Lees,et al. Guidelines for the management of inflammatory bowel disease in adults , 2011, Gut.
[14] A. Akobeng,et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.
[15] A. Griffiths,et al. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends , 2011, Inflammatory bowel diseases.
[16] J. Lindsay,et al. Inflammatory bowel disease in young people: The case for transitional clinics , 2010, Inflammatory bowel diseases.
[17] J. Fell,et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. , 2010, Journal of pediatric gastroenterology and nutrition.
[18] S. Hanauer,et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. , 2009, Gastroenterology.
[19] A. Griffiths,et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn’s Disease , 2009, The American Journal of Gastroenterology.
[20] A. Griffiths,et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI) , 2009, Inflammatory bowel diseases.
[21] C. Lees,et al. The safety profile of anti‐tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient‐years follow‐up , 2009, Alimentary pharmacology & therapeutics.
[22] R. Luchetti,et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[23] Julia Salleron,et al. Natural history of pediatric Crohn's disease: a population-based cohort study. , 2008, Gastroenterology.
[24] David C Wilson,et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. , 2008, Gastroenterology.
[25] A. Griffiths,et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.
[26] A. Griffiths,et al. Impact-iii Is a Valid, Reliable and Responsive Measure of Health-related Quality of Life in Pediatric Crohn's Disease , 2006 .
[27] J. Satsangi,et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.
[28] A. Griffiths,et al. The IMPACT Questionnaire: A Valid Measure of Health-Related Quality of Life in Pediatric Inflammatory Bowel Disease , 2002, Journal of pediatric gastroenterology and nutrition.
[29] M. Kamm,et al. Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.
[30] M. Corey,et al. Assessing activity of pediatric Crohn's disease: which index to use? , 1999, Gastroenterology.
[31] J T Boyle,et al. Development and validation of a pediatric Crohn's disease activity index. , 1991, Journal of pediatric gastroenterology and nutrition.
[32] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.